Image Source: Unsplash
 

• 100% technical buy signals
• 10 new highs and up 12.82% in the last month
• 54.90+ Weighted Alpha

The Chart of the Day belongs to the biopharmaceutical company PTC Therapeutics (PTCT).  I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation.  Since the Trend Seeker signaled a buy on 3/30 the stock gained 18.81%.

(Click on image to enlarge)

PTCT Price vs Daily Moving Averages

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart Technical Indicators:

• 100% technical buy signals
• 54.90+Weighted Alpha
• 83.01% gain in the last year
• Trend Seeker buy signal
• Above its 20, 50 and 100 day moving averages
• 10 new highs and up 12.82% in the last month
• Relative Strength Index 66.90%
• Technical support level at $53.29
• Recently traded at $58.29 with 50 day moving average of $50.66

Fundamental Factors:

• Market Cap $4.02 billion
• Revenue expected to grow 37.40% this year 
• Earnings estimated to increase 36.60% this year, and an additional 20.40% next year 

Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:

• Wall Street analysts issued 3 strong buy, 2 buy, 7 hold and 1 sell opinions on the stock
• Analysts price targets are between $35 and $71
• The individual investors following the stock on Motley Fool are split  voted and 22 to 13 for the stock to beat the market with the more experienced investors voting 57 to 6 for a different result
• Value Line give it their average rating of 2
• CFRAs MarketScope give it a hold rating
• 7,510 investors monitor the stock on Seeking Alpha

More By This Author:

Chart Of The Day: Cardinal Health - The Right Prescription
Chart Of The Day: CorVel - Under Followed Buy
Chart Of The Day: Boston Scientific - Medical Technology